Anti-Keratin 6A for IHC / Cytokeratin 6A, clone MSVA-606R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Cytokeratin 6A (KRT6A), commonly referred to as Cytokeratin-6 or CK6, is a type II intermediate filament protein expressed in stratified squamous epithelia and activated keratinocyte populations. It plays a key structural role in maintaining epithelial integrity and is strongly upregulated in hyperproliferative states such as wound healing, inflammation, and epithelial stress. Because of this inducible expression pattern, Cytokeratin 6A is widely used as a marker of squamous differentiation and epithelial activation in tissue-based analysis. Cytokeratin 6A Antibody for IHC enables clear visualization of these patterns in formalin-fixed, paraffin-embedded tissues, where cytoplasmic staining highlights keratinocyte populations with increased proliferative or regenerative activity.Cytokeratin 6A antibody, also referred to as KRT6A antibody or CK6 antibody in the literature, recognizes a cytoplasmic intermediate filament protein localized within keratinocytes and related epithelial cells. This Cytokeratin 6A Antibody for IHC is optimized for Tissue Microarray (TMA)-based immunohistochemistry, allowing standardized and high-throughput comparison of epithelial marker expression across large panels of normal and cancer tissues. In normal tissue microarrays, strong cytoplasmic HRP-DAB brown staining is consistently observed in stratified squamous epithelia including skin, esophagus, cervix, and tonsillar epithelium, with enrichment in suprabasal and activated keratinocyte layers, while most simple epithelia remain negative or show minimal staining.In cancer tissue microarrays, Cytokeratin 6A expression is frequently elevated in squamous cell carcinomas and tumors with basal-like or squamous differentiation. Cytoplasmic staining highlights tumor epithelial cells with hyperproliferative characteristics, providing a clear and interpretable pattern that supports identification of squamous lineage. This is particularly valuable in distinguishing squamous cell carcinomas from adenocarcinomas and other non-squamous malignancies within heterogeneous tumor samples. TMA-based analysis further demonstrates variability in KRT6A expression across tumor types, enabling comparative evaluation of epithelial activation states under identical staining conditions.Tissue Microarray (TMA) analysis enables direct side-by-side comparison of KRT6A expression across dozens of tissue types, demonstrating highly reproducible cytoplasmic staining in squamous epithelia and squamous-derived tumors with minimal background in non-expressing tissues. Clone MSVA-606R produces strong, well-defined staining across TMA panels, highlighting epithelial compartments with high contrast and consistency. The observed staining patterns align with known KRT6A biology and publicly available datasets such as the Human Protein Atlas, reinforcing the reliability of this antibody for large-scale immunohistochemistry studies.The inducible nature of KRT6A expression adds important biological context in IHC interpretation, as increased staining intensity often reflects epithelial activation, regeneration, or stress responses rather than baseline differentiation alone. This makes Cytokeratin 6A particularly useful in studies of tissue remodeling, inflammatory skin conditions, and tumor progression where epithelial dynamics are of interest.This antibody targets Cytokeratin 6A in research applications requiring robust and interpretable immunohistochemical detection of epithelial and squamous differentiation markers, making it well suited for Tissue Microarray-based studies, epithelial biology research, and tumor classification.This antibody is part of the Cytokeratin 6 antibody collection, where additional KRT6 antibodies for various applications can be explored.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.